Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CFO Sells 2,227 Shares of Stock

Key Points

• Halozyme Therapeutics CFO Nicole Labrosse sold 2,227 shares at an average price of $77.95, totaling $173,594.65, and now owns 22,079 shares.
• The company reported $1.54 EPS for the last quarter, exceeding estimates of $1.23 EPS, with revenue of $325.72 million, a 40.8% increase year-over-year.
• Wall Street analysts have varied ratings for Halozyme, with targets ranging from $55 to $80, leading to a consensus rating of "Hold".

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CFO Nicole Labrosse sold 2,227 shares of the business's stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $77.95, for a total value of $173,594.65. Following the transaction, the chief financial officer owned 22,079 shares in the company, valued at approximately $1,721,058.05. This represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Nicole Labrosse also recently made the following trade(s):

• On Wednesday, September 10th, Nicole Labrosse sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $75.71, for a total value of $1,514,200.00.

Halozyme Therapeutics Trading Down 0.9%

NASDAQ:HALO traded down $0.71 during mid-day trading on Tuesday, reaching $77.57. 1,812,412 shares of the company's stock traded hands, compared to its average volume of 1,968,064. Halozyme Therapeutics, Inc. has a 12-month low of $42.01 and a 12-month high of $79.50. The firm has a market capitalization of $9.07 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 0.43 and a beta of 1.19. The company has a debt-to-equity ratio of 4.54, a current ratio of 8.36 and a quick ratio of 7.01. The company has a 50 day moving average price of $67.54 and a 200-day moving average price of $61.22.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company had revenue of $325.72 million for the quarter, compared to the consensus estimate of $282.66 million. During the same quarter in the previous year, the business earned $0.91 EPS. Halozyme Therapeutics's revenue was up 40.8% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Institutional Investors Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of HALO. Two Sigma Advisers LP purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth $282,000. Voloridge Investment Management LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth $876,000. GF Fund Management CO. LTD. purchased a new stake in Halozyme Therapeutics in the 4th quarter worth $128,000. Armis Advisers LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth $295,000. Finally, Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the 4th quarter worth $29,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HALO. Morgan Stanley upped their target price on Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a report on Monday, August 18th. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. The Goldman Sachs Group began coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price target on the stock. Wall Street Zen downgraded Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. Finally, Zacks Research upgraded Halozyme Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 2nd. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat, Halozyme Therapeutics currently has a consensus rating of "Hold" and an average target price of $68.22.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.